We are live on ! Find out more
FLAM

First Light Asset Management Portfolio holdings

AUM $1.12B
1-Year Est. Return 114.45%
This Fund
S&P 500
This Quarter Est. Return
+2.79%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$720M
AUM Growth
-$49.3M
Cap. Flow
-$18.3M
Cap. Flow %
-2.54%
Top 10 Hldgs %
45.97%
Holding
78
New
15
Increased
29
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
ELGX
Endologix Inc
ELGX
+$16.8M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$13.2M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$11.5M
4
SIBN icon
SI-BONE Inc
SIBN
+$11.2M
5
CDXS icon
Codexis
CDXS
+$9.29M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$28.3M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$20.1M
3
HBIO icon
Harvard Bioscience
HBIO
+$19M
4
OMCL icon
Omnicell
OMCL
+$15.5M
5
DVAX
Dynavax Technologies
DVAX
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 74.38%
2 Communication Services 5.9%
3 Financials 0.98%
4 Energy 0.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$56.2M 7.8%
1,212,545
-1,009,176
-45% -$28.3M
OXFD
2
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$43.2M 6%
3,140,347
+396,868
+14% +$6.07M
MODN
3
DELISTED
MODEL N, INC.
MODN
$42.5M 5.9%
2,178,520
+2,926
+0.1% +$53.9K
ATRC icon
4
AtriCure
ATRC
$1.92B
$33.2M 4.61%
1,111,740
+197,433
+22% +$5.76M
NEO icon
5
NeoGenomics
NEO
$1.96B
$29.1M 4.04%
1,325,582
-279,029
-17% -$6.12M
OMCL icon
6
Omnicell
OMCL
$1.61B
$28.5M 3.96%
331,462
-190,587
-37% -$15.5M
MYOK
7
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$27M 3.75%
537,999
+98,364
+22% +$4.79M
NKTR icon
8
Nektar Therapeutics
NKTR
$2.39B
$25.4M 3.53%
47,585
-3,309
-7% -$1.66M
SPNE
9
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$23.9M 3.31%
1,800,997
+762
+0% +$10.7K
CDXS icon
10
Codexis
CDXS
$151M
$22.2M 3.08%
1,205,523
+481,763
+67% +$9.29M
IONS icon
11
Ionis Pharmaceuticals
IONS
$8.6B
$21M 2.92%
327,132
-284,030
-46% -$20.1M
XNCR icon
12
Xencor
XNCR
$1.5B
$20.4M 2.84%
499,344
-11,984
-2% -$394K
HRTX icon
13
Heron Therapeutics
HRTX
$93.9M
$20.4M 2.84%
1,098,723
-14,243
-1% -$285K
HALO icon
14
Halozyme
HALO
$9.79B
$18.3M 2.55%
1,067,813
-403,685
-27% -$6.51M
ELGX
15
DELISTED
Endologix Inc
ELGX
$17.8M 2.48%
+2,462,448
New +$16.8M
IMMU
16
DELISTED
Immunomedics Inc
IMMU
$17M 2.36%
1,223,483
-181,230
-13% -$2.73M
VCYT icon
17
Veracyte
VCYT
$3.7B
$16.8M 2.33%
589,099
-183,480
-24% -$4.58M
XENT
18
DELISTED
Intersect ENT, Inc
XENT
$15.2M 2.11%
668,893
-51,347
-7% -$1.38M
VTRS icon
19
Viatris
VTRS
$20.4B
$14.2M 1.97%
743,784
+417,879
+128% +$9.24M
AERI
20
DELISTED
Aerie Pharmaceuticals
AERI
$14.1M 1.96%
478,174
+4,108
+0.9% +$158K
SIBN icon
21
SI-BONE Inc
SIBN
$788M
$13.2M 1.84%
+651,319
New +$11.2M
AGIO icon
22
Agios Pharmaceuticals
AGIO
$1.79B
$12.4M 1.72%
+247,897
New +$13.2M
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$2.45B
$11.4M 1.59%
+180,017
New +$11.5M
VAPO
24
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$11.4M 1.59%
62,121
+12,247
+25% +$1.81M
LGND icon
25
Ligand Pharmaceuticals
LGND
$5.76B
$11.3M 1.56%
158,134
-52,755
-25% -$3.89M
1
2 3 4

Similar funds

AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
CT
Caldwell Trust Venice, Florida $1.12B AUM 21.31% 1-Year Est. Return
SL
Salomon & Ludwin Richmond, Virginia $1.12B AUM 14.38% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return

First Light Asset Management's Q2 2019 Portfolio in Review

As of Q2 2019, First Light Asset Management held 78 positions worth $720M, down 6.4% from $770M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

First Light Asset Management's Q2 2019 filing shows 15 new, 29 increased, 15 reduced and 5 closed positions. Its largest new stake was Endologix Inc: 2,462,448 shares worth $17.8M. The largest sale was Array Biopharma Inc, an estimated $28.3M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 75% a quarter earlier, followed by Communication Services and Financials.

  • First Light Asset Management's largest Q2 2019 buy was Endologix Inc: 2,462,448 shares worth $17.8M.
  • First Light Asset Management added most to Codexis in Q2 2019, an estimated $9.29M increase.
  • First Light Asset Management's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $28.3M.
  • First Light Asset Management fully exited Dynavax Technologies in Q2 2019, selling an estimated $12.5M.
  • First Light Asset Management's ten largest holdings make up 46% of its $720M portfolio in Q2 2019.
  • First Light Asset Management opened 15 new positions and closed 5 in Q2 2019.
  • First Light Asset Management's portfolio value fell 6.4% quarter-over-quarter to $720M.

Based on First Light Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.